These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34915975)

  • 1. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021.
    Brandal LT; MacDonald E; Veneti L; Ravlo T; Lange H; Naseer U; Feruglio S; Bragstad K; Hungnes O; Ødeskaug LE; Hagen F; Hanch-Hansen KE; Lind A; Watle SV; Taxt AM; Johansen M; Vold L; Aavitsland P; Nygård K; Madslien EH
    Euro Surveill; 2021 Dec; 26(50):. PubMed ID: 34915975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multistate Outbreak of SARS-CoV-2 B.1.1.529 (Omicron) Variant Infections Among Persons in a Social Network Attending a Convention - New York City, November 18-December 20, 2021.
    Smith-Jeffcoat SE; Pomeroy MA; Sleweon S; Sami S; Ricaldi JN; Gebru Y; Walker B; Brady S; Christenberry M; Bart S; Vostok J; Meyer S; Seys S; Markelz A; Ditto N; Newbern V; Thomas FJ; Thomas D; Cabredo E; Kellner S; Brown VR; Tate JE; Kirking HL
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):238-242. PubMed ID: 35176004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
    Pinato DJ; Aguilar-Company J; Ferrante D; Hanbury G; Bower M; Salazar R; Mirallas O; Sureda A; Plaja A; Cucurull M; Mesia R; Townsend S; Jackson A; Dalla Pria A; Newsom-Davis T; Handford J; Sita-Lumsden A; Apthorp E; Vincenzi B; Bertuzzi A; Brunet J; Lambertini M; Maluquer C; Pedrazzoli P; Biello F; Sinclair A; Bawany S; Khalique S; Rossi S; Rogers L; Murphy C; Belessiotis K; Carmona-García MC; Sharkey R; García-Illescas D; Rizzo G; Perachino M; Saoudi-Gonzalez N; Doonga K; Fox L; Roldán E; Gaidano G; Ruiz-Camps I; Bruna R; Patriarca A; Martinez-Vila C; Cantini L; Zambelli A; Giusti R; Mazzoni F; Caliman E; Santoro A; Grosso F; Parisi A; Queirolo P; Aujayeb A; Rimassa L; Prat A; Tucci M; Libertini M; Grisanti S; Mukherjee U; Diamantis N; Fusco V; Generali D; Provenzano S; Gennari A; Tabernero J; Cortellini A;
    Lancet Oncol; 2022 Jul; 23(7):865-875. PubMed ID: 35660139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overlapping Delta and Omicron Outbreaks During the COVID-19 Pandemic: Dynamic Panel Data Estimates.
    Lundberg AL; Lorenzo-Redondo R; Hultquist JF; Hawkins CA; Ozer EA; Welch SB; Prasad PVV; Achenbach CJ; White JI; Oehmke JF; Murphy RL; Havey RJ; Post LA
    JMIR Public Health Surveill; 2022 Jun; 8(6):e37377. PubMed ID: 35500140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
    Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Milder disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 Omicron variant compared with the Delta variant in Norway.
    Stålcrantz J; Kristoffersen AB; Bøås H; Veneti L; Seppälä E; Aasand N; Hungnes O; Kvåle R; Bragstad K; Buanes EA; Whittaker R
    Scand J Public Health; 2022 Aug; 50(6):676-682. PubMed ID: 35799474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
    Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
    Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical characteristics and outcomes of critically ill adults with SARS-CoV-2 infection during Delta and Omicron variant predominance periods: a single-hospital retrospective cohort study.
    Sankar K; Modi N; Polyak A; Directo MP; Johnson LR; Kho N; Isonaka SK; Pedraza I; Chen P; Modes ME
    BMJ Open Respir Res; 2023 Feb; 10(1):. PubMed ID: 36805880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of outbreak cases infected with the SARS-CoV-2 B.1.640 variant in a fully vaccinated elderly population, Normandy, France, November to December 2021.
    Mastrovito B; Naimi C; Kouam L; Naudot X; Fournier L; Spaccaferri G; Plantier JC; Soares A; De Oliveira F; Gueudin M; Jacomo V; Leroy C; Moisan A; Martel M
    Euro Surveill; 2022 Feb; 27(6):. PubMed ID: 35144722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
    Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 Vaccine Effectiveness during a Prison Outbreak when Omicron was the Dominant Circulating Variant-Zambia, December 2021.
    Simwanza J; Hines JZ; Sinyange D; Sinyange N; Mulenga C; Hanyinza S; Sakubita P; Langa N; Nowa H; Gardner P; Saasa N; Chitempa G; Simpungwe J; Malambo W; Hamainza B; Chipimo PJ; Kapata N; Kapina M; Musonda K; Liwewe M; Mwale C; Fwoloshi S; Mulenga LB; Agolory S; Mukonka V; Chilengi R
    Am J Trop Med Hyg; 2022 Nov; 107(5):1055-1059. PubMed ID: 36096406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom trajectories of post-COVID sequelae in patients with acute Delta or Omicron infection in Bergen, Norway.
    Iversen A; Blomberg B; Haug K; Kittang B; Özgümüs T; Cox RJ; Langeland N
    Front Public Health; 2024; 12():1320059. PubMed ID: 38504678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.
    Townsley H; Gahir J; Russell TW; Greenwood D; Carr EJ; Dyke M; Adams L; Miah M; Clayton B; Smith C; Miranda M; Mears HV; Bailey C; Black JRM; Fowler AS; Crawford M; Wilkinson K; Hutchinson M; Harvey R; O'Reilly N; Kelly G; Goldstone R; Beale R; Papineni P; Corrah T; Gilson R; Caidan S; Nicod J; Gamblin S; Kassiotis G; Libri V; Williams B; Gandhi S; Kucharski AJ; Swanton C; Bauer DLV; Wall EC
    PLoS One; 2024; 19(3):e0294897. PubMed ID: 38512960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outbreak caused by the SARS-CoV-2 Omicron variant in the psychiatric ward of a general hospital in Brazil.
    Vanni T; Menezes MS; Sudbrack LO; Futiwaki F; Bezerra LS; Cabral Filho S; Oliveira Neto E; Cortez PGP; Costa FJQ; Vieira LL; Roll MM; Araújo WN; Almiron M; Siqueira AM; Ribeiro LM; Ribeiro JF
    Rev Soc Bras Med Trop; 2022; 55():e0177. PubMed ID: 35946630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.
    Arabi M; Al-Najjar Y; Sharma O; Kamal I; Javed A; Gohil HS; Paul P; Al-Khalifa AM; Laws S; Zakaria D
    BMC Infect Dis; 2023 Jun; 23(1):432. PubMed ID: 37365490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics.
    Meo SA; Meo AS; Al-Jassir FF; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8012-8018. PubMed ID: 34982465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.